Business
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials
CNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCNBX Selects API Supplier Purisys to Support Planned IND Fillings and Phase I/II (a) Clinical Trials\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Md., Nov. 4, 2021\n\n\n\nTEL AVIV, Israel and BETHESDA, Md., Nov. 4, 2021 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today that it has signed an agreement with Purisys, a leading Active Pharmaceutical Iingredient (API) manufacturer, for supply of Good Manufacturing Practice (GMP) grade APIs required for the manufacturing of RCC-33, the company's colorectal cancer treatment drug candidate. Under said agreement, Purisys will also support CNBX throughout an IND filing process, including providing all necessary and related information concerning Chemistry Manufacturing and Controls (CMC) in the form of a comprehensive technical package to be presented to the FDA. APIs supplied under said agreement will be used by Company in Phase I/II (a) clinical studies that it is planning to launch in 2022.\nGabriel Yariv, Cannabics Pharmaceuticals' Executive Chairman, said: \"We have been carefully searching for an API supplier to support our planned IND fillings for quite some time now, and in Purisys we found all the various parameters we were looking for. Purisys is the leading provider of synthetically-derived cannabinoid APIs to researchers and product developers looking to navigate health authority-regulated pathways. Accordingly, we became confident that Purisys will be able to provide us with an ultra-high purity API product on the one hand, and with all the necessary regulatory and CMC related support required for our planned approach of the FDA on the other. I am pleased to report that this agreement marks an important step in the right direction for the company.\"\nJosh Hoerner, Purisys LLC. General Manager commented: \"We are excited about the opportu...